NL930038I2 - Farmaceutische preparaten, welke een invloed op demaagzuurafscheiding bezitten en ten minste een qu anidinothiazoolderivaat als werkzame stof bevattenalsmede de voor gebruik in dergelijke preparaten geschikte quanidinothiazoolderivaten. - Google Patents
Farmaceutische preparaten, welke een invloed op demaagzuurafscheiding bezitten en ten minste een qu anidinothiazoolderivaat als werkzame stof bevattenalsmede de voor gebruik in dergelijke preparaten geschikte quanidinothiazoolderivaten.Info
- Publication number
- NL930038I2 NL930038I2 NL930038C NL930038C NL930038I2 NL 930038 I2 NL930038 I2 NL 930038I2 NL 930038 C NL930038 C NL 930038C NL 930038 C NL930038 C NL 930038C NL 930038 I2 NL930038 I2 NL 930038I2
- Authority
- NL
- Netherlands
- Prior art keywords
- preparations
- quanidinothiazole
- anidinothiazole
- derivative
- influence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP54098906A JPS6056143B2 (ja) | 1979-08-02 | 1979-08-02 | アミジン誘導体ならびにその製造法 |
Publications (2)
Publication Number | Publication Date |
---|---|
NL930038I1 NL930038I1 (nl) | 1993-08-02 |
NL930038I2 true NL930038I2 (nl) | 1993-10-01 |
Family
ID=14232166
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NLAANVRAGE7909321,A NL180420C (nl) | 1979-08-02 | 1979-12-27 | Farmaceutische preparaten, welke een invloed op de maagzuurafscheiding bezitten en ten minste een guanidinothiazoolderivaat als werkzame stof bevatten alsmede de voor gebruik in dergelijke preparaten geschikte guanidinothiazoolderivaten. |
NL930038C NL930038I2 (nl) | 1979-08-02 | 1993-05-19 | Farmaceutische preparaten, welke een invloed op demaagzuurafscheiding bezitten en ten minste een qu anidinothiazoolderivaat als werkzame stof bevattenalsmede de voor gebruik in dergelijke preparaten geschikte quanidinothiazoolderivaten. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NLAANVRAGE7909321,A NL180420C (nl) | 1979-08-02 | 1979-12-27 | Farmaceutische preparaten, welke een invloed op de maagzuurafscheiding bezitten en ten minste een guanidinothiazoolderivaat als werkzame stof bevatten alsmede de voor gebruik in dergelijke preparaten geschikte guanidinothiazoolderivaten. |
Country Status (12)
Country | Link |
---|---|
US (1) | US4283408A (nl) |
JP (1) | JPS6056143B2 (nl) |
CA (2) | CA1134836A (nl) |
CH (1) | CH648027A5 (nl) |
DE (1) | DE2951675C2 (nl) |
ES (1) | ES487381A0 (nl) |
FR (1) | FR2462431B1 (nl) |
GB (1) | GB2055800B (nl) |
IT (1) | IT1119641B (nl) |
NL (2) | NL180420C (nl) |
PH (1) | PH15657A (nl) |
SE (1) | SE444317B (nl) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GR62452B (en) * | 1977-04-20 | 1979-04-12 | Ici Ltd | Preparation process of guanidine derivatives |
PH16099A (en) * | 1979-03-06 | 1983-06-24 | Yamanouchi Pharma Co Ltd | Guanidinothiazole compounds,process for preparing them and medical composition containing them |
GR71929B (nl) * | 1979-11-13 | 1983-08-19 | Ici Ltd | |
DE3168031D1 (en) * | 1980-07-30 | 1985-02-14 | Ici Plc | Guanidine derivatives |
US4382090A (en) * | 1980-10-02 | 1983-05-03 | Eli Lilly And Company | N-Thiazolylmethylthioalkyl-N'alkylamidines and related compounds |
IN158869B (nl) * | 1981-03-18 | 1987-02-07 | Ici Plc | |
DE3267110D1 (de) * | 1981-05-18 | 1985-12-05 | Ici Plc | Amidine derivatives |
DE3238867A1 (de) * | 1982-10-20 | 1984-04-26 | Ludwig Heumann & Co GmbH, 8500 Nürnberg | Heterocyclische verbindungen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
JPS59104370A (ja) * | 1982-12-03 | 1984-06-16 | Kotobuki Seiyaku Kk | チアゾ−ル誘導体及びその製造方法 |
JPS59227870A (ja) * | 1983-06-07 | 1984-12-21 | Yamanouchi Pharmaceut Co Ltd | 新規2−グアニジノチアゾリン誘導体ならびにその製造法 |
US4497810A (en) * | 1983-10-14 | 1985-02-05 | Merck & Co., Inc. | Thiatriazine dioxides as gastric anti-secretory agents |
US4663347A (en) | 1983-10-31 | 1987-05-05 | Merck Frosst Canada, Inc. | Benzofuran 2-carboxylic acid esters useful as inhibitors of leukotriene biosynthesis |
CA1269382A (en) * | 1984-04-18 | 1990-05-22 | Jose A. Ortiz | Anti-ulceric sulfonamidines |
US4560690A (en) * | 1984-04-30 | 1985-12-24 | Pfizer Inc. | 2-(N-substituted guanidino)-4-hetero-arylthiazole antiulcer agents |
JPS6160673A (ja) * | 1984-08-30 | 1986-03-28 | Yamanouchi Pharmaceut Co Ltd | グアニジノチアゾ−ル誘導体の製造法 |
CA1309557C (en) | 1985-06-18 | 1992-10-27 | Robert N. Young | Leukotriene antagonists |
HU194845B (en) * | 1985-09-11 | 1988-03-28 | Richter Gedeon Vegyeszet | Process for production of n-sulphamil-3-/2-guanidintiazolil-4-methil-tio/-propion-amidin |
DE3786030T2 (de) | 1986-03-27 | 1993-12-02 | Merck Frosst Canada Inc | Tetrahydrocarbazole Ester. |
DE3644246A1 (de) * | 1986-06-20 | 1987-12-23 | Uriach & Cia Sa J | Verfahren zur herstelung von 3-(((2-((aminoiminomethyl)-amino)-4-thiazolyl)-methyl)-thio)-n-(aminosulfonyl)-propanimidamid |
HU196775B (en) * | 1986-08-05 | 1989-01-30 | Richter Gedeon Vegyeszet | Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances |
ES2008810A6 (es) * | 1988-07-18 | 1989-08-01 | Marga Investigacion | Procedimiento de preparacion de derivados de n-sulfamil-propionamidina. |
HUT61980A (en) | 1990-10-12 | 1993-03-29 | Merck Frosst Canada Inc | Process for producing saturated hydroxyalkylquinoline acids and pharmaceutical compositions comprising such compounds as active ingredient |
US5294433A (en) * | 1992-04-15 | 1994-03-15 | The Procter & Gamble Company | Use of H-2 antagonists for treatment of gingivitis |
CA2110313C (en) * | 1992-12-01 | 2004-10-26 | Edward John Roche | Pharmaceutical compositions containing a guanidinothiazole compound and antacids |
US5410054A (en) * | 1993-07-20 | 1995-04-25 | Merck Frosst Canada, Inc. | Heteroaryl quinolines as inhibitors of leukotriene biosynthesis |
US5593696A (en) * | 1994-11-21 | 1997-01-14 | Mcneil-Ppc, Inc. | Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders |
US5650421A (en) * | 1995-03-31 | 1997-07-22 | Baxter International Inc. | Premixed famotidine formulation |
US5667794A (en) * | 1995-05-02 | 1997-09-16 | Merck & Co., Inc. | Heartburn treatment |
US5854267A (en) * | 1995-06-02 | 1998-12-29 | Merck & Co., Inc. | Method for preventing heartburn |
KR0168978B1 (ko) * | 1995-07-12 | 1999-01-15 | 김종인 | 헤테로고리 접합 티아졸 유도체 |
US5989588A (en) * | 1996-10-04 | 1999-11-23 | Merck & Co., Inc. | Methods and compositions for preventing and treating heartburn |
US6949264B1 (en) | 1996-11-27 | 2005-09-27 | Wm. Wrigley Jr. Company | Nutraceuticals or nutritional supplements and method of making |
US5856500A (en) * | 1997-03-11 | 1999-01-05 | Albemarle Corporation | Synthesis of thiazole derivatives |
US5731442A (en) * | 1997-03-11 | 1998-03-24 | Albemarle Corporation | Synthesis of thiazole derivatives |
AU772188B2 (en) * | 1998-11-17 | 2004-04-08 | Nitromed, Inc. | Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use |
US6531114B1 (en) | 1999-04-06 | 2003-03-11 | Wm. Wrigley Jr. Company | Sildenafil citrate chewing gum formulations and methods of using the same |
US6586023B1 (en) | 1998-12-15 | 2003-07-01 | Wm. Wrigley Jr. Company | Process for controlling release of active agents from a chewing gum coating and product thereof |
US7163705B2 (en) | 1998-12-15 | 2007-01-16 | Wm. Wrigley Jr. Company | Coated chewing gum product and method of making |
US6627234B1 (en) | 1998-12-15 | 2003-09-30 | Wm. Wrigley Jr. Company | Method of producing active agent coated chewing gum products |
US6270807B1 (en) | 1999-03-02 | 2001-08-07 | L. Perrigo Company | Taste-masked pharmaceutical composition |
US6773716B2 (en) | 1999-04-06 | 2004-08-10 | Wm. Wrigley Jr. Company | Over-coated chewing gum formulations |
RU2001126555A (ru) * | 1999-04-06 | 2003-06-20 | Вм. Ригли Дж. Компани (Us) | Составы фармацевтической жевательной резинки |
US6322806B1 (en) | 1999-04-06 | 2001-11-27 | Wm. Wrigley Jr. Company | Over-coated chewing gum formulations including tableted center |
US6355265B1 (en) | 1999-04-06 | 2002-03-12 | Wm. Wrigley Jr. Company | Over-coated chewing gum formulations |
US7935362B2 (en) | 1999-04-06 | 2011-05-03 | Wm. Wrigley Jr. Company | Over-coated product including consumable center and medicament |
US6541048B2 (en) | 1999-09-02 | 2003-04-01 | Wm. Wrigley Jr. Company | Coated chewing gum products containing an acid blocker and process of preparing |
US6645535B2 (en) | 1999-09-02 | 2003-11-11 | Wm. Wrigley Jr. Company | Method of making coated chewing gum products containing various antacids |
US6663849B1 (en) | 2000-09-01 | 2003-12-16 | Wm. Wrigley Jr. Company | Antacid chewing gum products coated with high viscosity materials |
US6569472B1 (en) | 2000-09-01 | 2003-05-27 | Wm. Wrigley Jr. Company | Coated chewing gum products containing antacid and method of making |
WO2001021147A1 (en) | 1999-09-20 | 2001-03-29 | Mastercare | Diet and weight control gum and sucker |
US9253991B2 (en) | 1999-09-20 | 2016-02-09 | Jack Barreca | Chewing gum with B vitamins |
US9387168B2 (en) | 1999-09-20 | 2016-07-12 | Jack Barreca | Chewing gum with tomatidine |
US7115288B2 (en) | 2000-06-09 | 2006-10-03 | Wm. Wrigley Jr. Company | Method for making coated chewing gum products with a coating including an aldehyde flavor and a dipeptide sweetener |
US6572900B1 (en) | 2000-06-09 | 2003-06-03 | Wm. Wrigley, Jr. Company | Method for making coated chewing gum products including a high-intensity sweetener |
US6444241B1 (en) | 2000-08-30 | 2002-09-03 | Wm. Wrigley Jr. Company | Caffeine coated chewing gum product and process of making |
US6579545B2 (en) | 2000-12-22 | 2003-06-17 | Wm. Wrigley Jr. Company | Coated chewing gum products containing an antigas agent |
SE0101379D0 (sv) * | 2001-04-18 | 2001-04-18 | Diabact Ab | Komposition som hämmar utsöndring av magsyra |
SE0203065D0 (sv) * | 2002-10-16 | 2002-10-16 | Diabact Ab | Gastric acid secretion inhibiting composition |
TW200517114A (en) | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
WO2006071659A1 (en) * | 2004-12-29 | 2006-07-06 | Trustees Of Boston University | Delivery of h2 antagonists |
US8067451B2 (en) * | 2006-07-18 | 2011-11-29 | Horizon Pharma Usa, Inc. | Methods and medicaments for administration of ibuprofen |
US20080020040A1 (en) * | 2006-07-18 | 2008-01-24 | Horizon Therapeutics, Inc. | Unit dose form for administration of ibuprofen |
WO2007012022A2 (en) * | 2005-07-18 | 2007-01-25 | Horizon Therapeutics, Inc. | Unit dose form with ibuprofen-famotidine admixture |
US20080021078A1 (en) * | 2006-07-18 | 2008-01-24 | Horizon Therapeutics, Inc. | Methods and medicaments for administration of ibuprofen |
EP2218442A1 (en) | 2005-11-09 | 2010-08-18 | CombinatoRx, Inc. | Methods, compositions, and kits for the treatment of ophthalmic disorders |
AU2007275360B2 (en) | 2006-07-18 | 2013-05-16 | Horizon Medicines Llc | Methods and medicaments for administration of ibuprofen |
US8067033B2 (en) | 2007-11-30 | 2011-11-29 | Horizon Pharma Usa, Inc. | Stable compositions of famotidine and ibuprofen |
US20100297224A1 (en) * | 2006-08-31 | 2010-11-25 | Horizon Therapeutics, Inc. | NSAID Dose Unit Formulations with H2-Receptor Antagonists and Methods of Use |
EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
US7718649B1 (en) | 2006-11-10 | 2010-05-18 | Pisgah Labs, Inc. | Physical states of a pharmaceutical drug substance |
US8039461B1 (en) | 2006-11-10 | 2011-10-18 | Pisgah Laboratories, Inc. | Physical states of a pharmaceutical drug substance |
US20090069395A1 (en) * | 2007-09-09 | 2009-03-12 | Protia, Llc | Deuterium-enriched famotidine |
PL2240018T3 (pl) * | 2008-01-04 | 2017-01-31 | Schabar Res Ass Llc | Kompozycja zawierająca środek przeciwbólowy i przeciwhistaminowy |
US8883863B1 (en) | 2008-04-03 | 2014-11-11 | Pisgah Laboratories, Inc. | Safety of psuedoephedrine drug products |
WO2010021681A2 (en) * | 2008-08-18 | 2010-02-25 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
TW201105233A (en) | 2009-05-11 | 2011-02-16 | Agraquest Inc | Compounds derived from muscodor fungi |
US20110130711A1 (en) * | 2009-11-19 | 2011-06-02 | Follica, Inc. | Hair growth treatment |
WO2013135852A1 (en) | 2012-03-15 | 2013-09-19 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof |
JP6378179B2 (ja) * | 2013-07-03 | 2018-08-22 | 株式会社新日本科学 | 新規化合物,有機カチオントランスポーター3の検出剤及び活性阻害剤 |
CN105377235A (zh) | 2013-07-19 | 2016-03-02 | 勃林格殷格翰动物保健有限公司 | 含有防腐的醚化的环糊精衍生物的液体水性药物组合物 |
BR122019024673B1 (pt) | 2013-12-04 | 2023-04-11 | Boehringer Ingelheim Vetmedica Gmbh | Composições farmacêuticas aprimoradas de pimobendan |
EP2929884A1 (en) | 2014-04-11 | 2015-10-14 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical combinations of dabigatran and h2-receptor antagonists |
WO2015163832A1 (en) | 2014-04-25 | 2015-10-29 | Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. | An ibuprofen and famotidine combined composition having improved stability |
WO2015169957A1 (en) | 2014-05-09 | 2015-11-12 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical combinations of rivaroxaban and h2-receptor antagonists |
US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
TR201618765A2 (tr) | 2016-12-16 | 2018-07-23 | Imuneks Farma Ilac Sanayi Ve Ticaret Anonim Sirketi | Ağrı ve enflamasyonun tedavisi için steroid olmayan anti-enflamatuvar ilaçlar ve H2 reseptörü antagonisti kombinasyonları. |
US11324727B2 (en) | 2020-07-15 | 2022-05-10 | Schabar Research Associates, Llc | Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn |
JP2023534810A (ja) | 2020-07-15 | 2023-08-14 | シャバー リサーチ アソシエイツ エルエルシー | 急性痛の処置並びに胸やけの重症度及び/又はリスクの低減のための、イブプロフェン及びファモチジンから構成される単位経口用量組成物 |
EP4196793A1 (en) | 2020-08-11 | 2023-06-21 | Université de Strasbourg | H2 blockers targeting liver macrophages for the prevention and treatment of liver disease and cancer |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1338169A (en) * | 1971-03-09 | 1973-11-21 | Smith Kline French Lab | Ureas thioureas and guanidines |
US4165378A (en) * | 1977-04-20 | 1979-08-21 | Ici Americas Inc. | Guanidine derivatives of imidazoles and thiazoles |
GR62452B (en) * | 1977-04-20 | 1979-04-12 | Ici Ltd | Preparation process of guanidine derivatives |
-
1979
- 1979-08-02 JP JP54098906A patent/JPS6056143B2/ja not_active Expired
- 1979-12-20 GB GB7943945A patent/GB2055800B/en not_active Expired
- 1979-12-21 DE DE2951675A patent/DE2951675C2/de not_active Expired
- 1979-12-21 PH PH23454A patent/PH15657A/en unknown
- 1979-12-21 SE SE7910568A patent/SE444317B/sv not_active IP Right Cessation
- 1979-12-24 CH CH11362/79A patent/CH648027A5/de not_active IP Right Cessation
- 1979-12-27 US US06/107,629 patent/US4283408A/en not_active Expired - Lifetime
- 1979-12-27 NL NLAANVRAGE7909321,A patent/NL180420C/nl not_active IP Right Cessation
- 1979-12-28 FR FR797931938A patent/FR2462431B1/fr not_active Expired
- 1979-12-28 IT IT69498/79A patent/IT1119641B/it active Protection Beyond IP Right Term
- 1979-12-28 CA CA000342699A patent/CA1134836A/en not_active Expired
- 1979-12-28 ES ES487381A patent/ES487381A0/es active Granted
-
1986
- 1986-10-31 CA CA000521982A patent/CA1222763B/en not_active Expired
-
1993
- 1993-05-19 NL NL930038C patent/NL930038I2/nl unknown
Also Published As
Publication number | Publication date |
---|---|
DE2951675C2 (de) | 1982-07-01 |
CA1222763B (en) | 1987-06-09 |
IT1119641B (it) | 1986-03-10 |
US4283408A (en) | 1981-08-11 |
GB2055800A (en) | 1981-03-11 |
JPS5622770A (en) | 1981-03-03 |
ES8100281A1 (es) | 1980-11-01 |
DE2951675A1 (de) | 1981-02-05 |
GB2055800B (en) | 1983-05-11 |
FR2462431A1 (fr) | 1981-02-13 |
NL930038I1 (nl) | 1993-08-02 |
SE7910568L (sv) | 1981-02-03 |
SE444317B (sv) | 1986-04-07 |
CH648027A5 (de) | 1985-02-28 |
NL180420B (nl) | 1986-09-16 |
PH15657A (en) | 1983-03-11 |
IT7969498A0 (it) | 1979-12-28 |
NL7909321A (nl) | 1981-02-04 |
CA1134836A (en) | 1982-11-02 |
NL180420C (nl) | 1987-02-16 |
JPS6056143B2 (ja) | 1985-12-09 |
ES487381A0 (es) | 1980-11-01 |
FR2462431B1 (fr) | 1985-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NL930038I2 (nl) | Farmaceutische preparaten, welke een invloed op demaagzuurafscheiding bezitten en ten minste een qu anidinothiazoolderivaat als werkzame stof bevattenalsmede de voor gebruik in dergelijke preparaten geschikte quanidinothiazoolderivaten. | |
NL8103768A (nl) | Heterocyclische verbindingen, werkwijze ter bereiding daarvan, alsmede farmaceutische preparaten die deze verbindingen als actieve component bevatten. | |
NL173978C (nl) | Fysiologisch werkzame verbinding, esterastine genaamd, en werkwijze voor het bereiden daarvan langs microbiologische weg, alsmede farmaceutische preparaten met immunosuppressieve werking die de verbinding bevatten. | |
NL188219C (nl) | Camptothecinederivaten, werkwijze voor het bereiden daarvan, farmaceutische preparaten met anti-tumorwerking, werkwijze voor het bereiden daarvan. | |
NL183080C (nl) | Farmaceutisch preparaat, dat een (+)-catecholderivaat als werkzame stof bevat alsmede het voor gebruik in een dergelijk preparaat geschikte (+)-catecholderivaat. | |
NL187268C (nl) | Farmaceutische samenstelling tegen kanker en werkwijze voor de bereiding van de actieve stof. | |
NL184895C (nl) | Pyrido(3,4-f)-indoolderivaten met cytostatische eigenschappen, werkwijze voor het bereiden daarvan alsmede farmaceutische preparaten die dergelijke verbindingen bevatten. | |
NL7811220A (nl) | Cefalosporanzuurderivaten, werkwijzen voor de bereiding daarvan, farmaceutische preparaten. | |
NL188981C (nl) | Farmaceutisch preparaat met kankerbestrijdende werking, alsmede antrachinonderivaten die geschikt zijn als werkzaam bestanddeel daarvan. | |
NL184467C (nl) | 6-oxo-prostaglandine e1 derivaten, werkwijze voor de bereiding daarvan en farmaceutische preparaten, die deze bevatten. | |
NL187485C (nl) | Prostaglandinederivaten, werkwijze voor de bereiding daarvan en farmaceutisch preparaat. | |
NL180664C (nl) | 1,8-alkyleen-3-carboxy-4-oxo-7-piperazinochinolinederivaten, werkwijze voor de bereiding daarvan en anti-microbiele preparaten die een dergelijke verbinding als werkzame stof bevatten. | |
NL187069C (nl) | N-acyl 3-(1-amino-3-methylbutyl)-8-hydroxy-3,4-dihydro-isocoumarine verbinding, werkwijze voor de bereiding daarvan en farmaceutisch preparaat. | |
NL7612937A (nl) | Thienamycinederivaten en farmaceutische prepa- raten alsmede werkwijze voor het bereiden daarvan. | |
NL7811292A (nl) | Pyridoxol-derivaat, werkwijze voor de bereiding daarvan en farmaceutische preparaten die het bevatten. | |
NL175524C (nl) | Glycerolderivaten, deze bevattende farmaceutische preparaten, en werkwijze voor het bereiden daarvan. | |
NL7909200A (nl) | N-gesubstitueerde trifluorethylaminen, farmaceutische preparaten met als werkzaam bestanddeel een dergelijk n-gesubstitueerd trifluorethylamine erin, alsmede werkwijzen voor de bereiding van de werkzame bestand- delen. | |
NL188944C (nl) | Werkwijze voor het bereiden van omega-aminoalkoxybenzeenderivaten alsmede werkwijze voor het bereiden van farmaceutische preparaten met toepassing daarvan, als werkzame verbinding. | |
NL7802826A (nl) | Thienamycinederivaat, werkwijze voor het bereiden daarvan, alsmede farmaceutische preparaten. | |
NL184160C (nl) | Tegen schimmels werkzame imidazool-derivaten, preparaten die ze bevatten en werkwijze voor de bereiding daarvan. | |
NL7602993A (nl) | Fysiologisch werkzame gesubstitueerde tetrazolen, alsmede werkwijze voor de bereiding daarvan en voor preparaten met deze verbindingen als aktie- ve stof. | |
NL189352C (nl) | Werkwijze voor het bereiden van optisch actieve benzoxazolylpropionzuurderivaten, alsmede van preparaten met deze verbindingen als actieve stof. | |
NL7806321A (nl) | Piperazinecarbodithiozuurderivaten, werkwijze voor de bereiding daarvan en geneesmiddelen daaruit. | |
NL187974C (nl) | O-gesubstitueerde oximderivaten, werkwijze voor de bereiding daarvan, alsmede farmaceutische preparaten, die dergelijke verbindingen bevatten. | |
NL8004350A (nl) | Gehalogeneerde 15-hydroxy-e-homoeburnaanderivaten, werkwijze voor de bereiding hiervan en de toepassing als geneesmiddel. |